A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
|Articles|August 11, 2021
Pharmacy Clinical Pearl of the Day: First-line Treatment Options for Heart Disease
Author(s)Saro Arakelians, PharmD
The goal of treating heart failure is to reduce symptoms, improve heart function, and increase ejection fraction.
Advertisement
Clinical Pearl of the Day:
Heart failure disease first-line treatment options:
- ACE inhibitors/ARB or ARNI (Entresto) and Beta blockers plus aldosterone blockers (for Class II-IV heart failure with GFR>30ml, K+<5)
- SGLT-2 Inhibitor: If volume is overloaded add Loop diuretic
Explanation:
When it comes to heart failure treatment options, patients should be started on beta blockers, ACE inhibitors, ARBs, or ARNIs.
If the dosages are maxed out, patients do not tolerate, or patients do not benefit from these first-line options, then prescribers should be adding aldosterone blockers or SGLT-2 inhibitors
The goal is to reduce the symptoms, improve heart function, and increase ejection fraction.
Advertisement
Related to this article
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg vs placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5